title: Outcome after surgical resection of intraductal papillary and mucinous tumors of the pancreas.
abstract: OBJECTIVE
  Treatment of intraductal papillary and mucinous tumors of pancreas (IPMT) usually requires surgery. The objective of this study was to evaluate the risk of recurrence in patients after surgery according to the histological nature of the neoplasm and the type of surgery.
  
  
  METHODS
  The outcome of 45 patients who underwent partial pancreatectomy (n = 35) or total pancreatectomy (n = 10) for IPMT was studied according to the nature of the neoplasm (invasive carcinoma or noninvasive neoplasm), type of surgery (partial or total pancreatectomy), and lymph nodes status.
  
  
  RESULTS
  The overall 3-yr actuarial survival rate was 83%. Death occurred in seven of 20 (35%) patients with invasive carcinoma and in one of 26 (4%) patients with noninvasive tumors (p<0.05). There were two recurrences in the seven patients with noninvasive neoplasm who underwent partial pancreatectomy with involved resection margins, and none in the 13 patients with disease-free margins. In patients with invasive carcinoma, there was one recurrence after total pancreatectomy, six after partial pancreatectomy with disease-free margins and six after partial pancreatectomy with involved margins. In patients with invasive carcinoma, total pancreatectomy and the absence of lymph nodes involvement were independently associated with a low risk of recurrence.
  
  
  CONCLUSIONS
  IPMT may be managed as follows: 1) in patients with noninvasive neoplasms, partial pancreatic resection should be guided by frozen section examination until disease-free margins are obtained; and 2) in patients with invasive carcinoma, total pancreatectomy seems most likely to cure the patient, but should be discussed according to the general status and the age.
authors.affiliation: Department of Gastroenterology, Laennec Hospital, Paris, France.
authors.forename: E
authors.initials: E
authors.lastname: Cuillerier
authors.forename: C
authors.initials: C
authors.lastname: Cellier
authors.forename: L
authors.initials: L
authors.lastname: Palazzo
authors.forename: J
authors.initials: J
authors.lastname: Devière
authors.forename: P
authors.initials: P
authors.lastname: Wind
authors.forename: F
authors.initials: F
authors.lastname: Rickaert
authors.forename: P H
authors.initials: PH
authors.lastname: Cugnenc
authors.forename: M
authors.initials: M
authors.lastname: Cremer
authors.forename: J P
authors.initials: JP
authors.lastname: Barbier
mesh_terms: D000206:Actuarial Analysis; D002288:Adenocarcinoma, Mucinous / Q000473:pathology / Q000601:surgery*; D000328:Adult; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D002291:Carcinoma, Papillary / Q000473:pathology / Q000601:surgery*; D005260:Female; D005500:Follow-Up Studies; D005629:Frozen Sections; D006801:Humans; D008198:Lymph Nodes / Q000473:pathology; D008297:Male; D008875:Middle Aged; D015580:Mohs Surgery; D009361:Neoplasm Invasiveness; D009364:Neoplasm Recurrence, Local / Q000473:pathology; D009367:Neoplasm Staging; D010180:Pancreatectomy / Q000145:classification; D010183:Pancreatic Ducts / Q000473:pathology*; D010190:Pancreatic Neoplasms / Q000473:pathology / Q000601:surgery*; D012307:Risk Factors; D015996:Survival Rate; D016896:Treatment Outcome